Sirolimus
- PDF / 169,559 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 88 Downloads / 144 Views
1
S
Fatal respiratory infection secondary to off-label use: case report In a retrospective study of 26 paediatric patients, who received off-label therapy with sirolimus for Kaposiform hemangioendothelioma (KHE) between March 2012 and December 2016, one patient was described [exact age not stated; sex not stated], who developed a respiratory infection secondary to sirolimus. The patient, who had KHE, started receiving oral sirolimus 0.8 mg/m2 twice daily. However, the patient subsequently developed a severe respiratory infection [duration of treatment to reaction onset not stated], which was attributed to the immunosuppression effect of sirolimus. The patient died due to complications of the infection. Author comment: "The patient had a severe respiratory infection which may have resulted from sirolimus-induced immunosuppression." "In 2010 Blatt et al.10 reported the first case involving the off-label use of sirolimus in a child with life-threatening KHE." "We also reported our primary experience and concluded that sirolimus is a potential therapy for refractory KHE." Wang Z, et al. Sirolimus therapy for kaposiform hemangioendothelioma with longterm follow-up. Journal of Dermatology 46: 956-961, No. 11, Nov 2019. Available 803437294 from: URL: http://doi.org/10.1111/1346-8138.15076 - China
0114-9954/19/1781-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 30 Nov 2019 No. 1781
Data Loading...
